Unmet needs in hypertension: Challenges and opportunities

Jackson, Joseph; Mérat, Patrick

doi:10.1007/s11906-996-0021-z

Cited by 3 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the shortcomings mentioned above, we believe that the current analysis demonstrates that there is a disparity between the preferences of those with hypertension, as compared to normotensive individuals and clinicians who care for hypertensive patients. We believe this information offers clues as to why many individuals with hypertension minimize the significance of the disease and its effects, which in turn May contribute to difficulties with hypertension treatment compliance 32,33 . Based on the findings in this study, we feel it is crucial for clinicians who manage patients with systemic arterial hypertension to routinely reassess compliance of their patients and include appropriate education and reinforcement in their care.…”

Section: Discussionmentioning

confidence: 75%

The Quality of Life of Patients With Hypertension

Stein

Brown

et al. 2002

J of Clinical Hypertension

View full text Add to dashboard Cite

The authors evaluated the self-reported quality of life in patients with systemic arterial hypertension and assessed whether clinicians and normotensive respondents from the general public appreciate the impact that hypertension has on health-related quality of life. A quality-of-life questionnaire was completed by 385 individuals: persons with hypertension (n=188), normotensive persons (n=148), and clinicians (n=49). A utility score, which represents one's self-perceived health-related quality of life, was generated for each group by using standardized time tradeoff questionnaires. Quality of life with hypertension was judged to be significantly higher according to affected individuals (mean utility score, 0.980), compared with normotensive persons (mean utility score, 0.948) and clinicians (mean utility score, 0.942), who were asked to assume that they had hypertension (p<0.0005). Clinicians and normotensive individuals tend to overemphasize the impact that hypertension has on quality of life, as compared to affected patients. The relatively low impact that hypertensive individuals indicate high blood pressure has on their quality of life may contribute to their lack of compliance with treatment regimens.

show abstract

Section: Discussionmentioning

confidence: 75%

The Quality of Life of Patients With Hypertension

Stein

Brown

et al. 2002

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…Patient compliance with antihypertensive therapy is particularly poor because mild-to-moderate hypertension is a condition requiring lifelong treatment, and many patients feel worse on therapy than they do when untreated [19][20][21][22][23][24]. The development of better-tolerated antihypertensive drugs might significantly improve the effectiveness of treatment and its impact in term of cardiovascular prevention and reduce the proportion of patients who do not achieve benefit from an effective treatment strategy.…”

Section: Discussionmentioning

confidence: 99%

Improved Tolerability of the Dihydropyridine Calcium-Channel Antagonist Lercanidipine: The Lercanidipine Challenge Trial

et al. 2003

View full text Add to dashboard Cite

Pharmacoeconomic Burden of Undertreating Hypertension

Esposti¹,

Valpiani²

2004

PharmacoEconomics

View full text Add to dashboard Cite

Many studies have shown the importance of antihypertensive drug therapy as a factor in reducing the risk of cardiovascular morbidity and mortality, and in containing the cost of managing hypertension and its complications. Nevertheless, the evidence in clinical practice indicates about half of hypertensive patients do not receive pharmacological treatment and about half of treated patients do not achieve blood pressure level control. Undertreating hypertension is the leading cause of failure in drug therapy effectiveness and cost effectiveness. The pharmacoeconomic burden of undertreating hypertension can be defined as the clinical (number of cardiovascular events) and economic (costs of managing cardiovascular events) consequences that would have been avoided by adequate control of blood pressure levels. In the last few years, the increase in this burden and the restriction of budget constraints has raised the awareness of healthcare providers with regards to the need to achieve better performance and to improve disease management of hypertension. This review aims to present the current situation regarding the pharmacoeconomic burden of undertreating hypertension by identifying the key issues of this medical condition, defining and measuring the extent of undertreatment, defining and measuring costs associated with undertreatment, and discussing some fundamental aspects of disease management for hypertension. The pharmacoeconomic burden of undertreating hypertension appears to be an extremely important phenomenon for which there is currently only very limited adequate research. The present dearth of appropriate data can be largely attributed to the lack of epidemiological studies in clinical practice. Future studies are necessary for a more precise quantification of the therapeutic and economic impact of undertreating arterial hypertension in clinical practice (appropriateness studies) and for more precise selection of antihypertensive drugs on the basis of the different cost-effectiveness profiles detected in 'real world' settings (cost-effectiveness studies).

show abstract

Unmet needs in hypertension: Challenges and opportunities

Cited by 3 publications

References 40 publications

The Quality of Life of Patients With Hypertension

The Quality of Life of Patients With Hypertension

Improved Tolerability of the Dihydropyridine Calcium-Channel Antagonist Lercanidipine: The Lercanidipine Challenge Trial

Pharmacoeconomic Burden of Undertreating Hypertension

Contact Info

Product

Resources

About